Bavituximab
Names
[ CAS No. ]:
648904-28-3
[ Name ]:
Bavituximab
Biological Activity
[Description]:
Bavituximab (Anti-Human Phosphatidylserine Recombinant Antibody) is a phosphatidylserine (PS)-targeting monoclonal antibody, suppresses tumor growth by targeting tumor vasculature and reactivating antitumor immunity. Bavituximab plus Paclitaxel (HY-B0015) and Carboplatin (HY-17393), have enhanced inhibition on non-small-cell lung cancer[1].
[Related Catalog]:
[Target]
Phosphatidylserine (PS)[1]
[In Vitro]
Bavituximab binds to exposed phosphatidylserine (PS) molecules via the serum protein, β2-glycoprotein 1 (β2GP1)[1]. Bavituximab binds PS to induces antibody-dependent cellular cytotoxicity, resulting in tumor vessel destruction[1]. Bavituximab (10 μg/mL; 48 h) binds to exposed phosphatidylserine (PS) via 10 μM Sorafenib inducing exposure in HUVEC and bEnd.3 cells[2].
[In Vivo]
Sorafenib induces exposure of anionic phospholipids in tumor model in mice. Bavituximab (100 μg/mouse; i.v.; single dose; 48 h after Sorafenib treatment) traces phosphatidylserine exposure in vivo[2]. Animal Model: Mice bearing subcutaneous PLC/PRF/5, C3A, and Huh7 tumors[2] Dosage: 100 μg/mouse (Bavituximab/β2GP1) Administration: Intravenous injection single dose; 48 h after sorafenib treatment (100 mg/kg; p.o.; single dose) Result: Traced phosphatidylserine exposure in vivo in mice with tumors.
[References]
Chemical & Physical Properties
No Any Chemical & Physical Properties
Related Compounds
The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.